{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:49:01Z","timestamp":1787237341020,"version":"build-2736575974"},"reference-count":136,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ctrv.2013.03.006","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T04:45:48Z","timestamp":1365223548000},"page":"851-861","source":"Crossref","is-referenced-by-count":85,"title":["Older and new purine nucleoside analogs for patients with acute leukemias"],"prefix":"10.1016","volume":"39","author":[{"given":"Pawel","family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.03.006_b0005","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.03.006_b0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1067\/mps.2002.121791","article-title":"Acute myelogenous leukemia","volume":"32","author":"Aquino","year":"2002","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.ctrv.2013.03.006_b0015","unstructured":"Atlanta GACS. Cancer facts and figures. 2012."},{"key":"10.1016\/j.ctrv.2013.03.006_b0020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2174\/092986711794480104","article-title":"Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity","volume":"18","author":"Robak","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ctrv.2013.03.006_b0025","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.clinthera.2009.11.017","article-title":"Current and emerging therapies for acute myeloid leukemia","volume":"2","author":"Robak","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.ctrv.2013.03.006_b0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0272-2712(18)30073-8","article-title":"Acute lymphoblastic leukemia","volume":"20","author":"Farhi","year":"2000","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.ctrv.2013.03.006_b0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.03.006_b0040","first-page":"540","article-title":"New approaches in acute lymphoblastic leukemia in adults: where do we go?","volume":"27","author":"Hoelzer","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.03.006_b0050","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.ctrv.2013.03.006_b0055","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1365-2141.2003.04336.x","article-title":"Mechanism of action of purine analogues in chronic lymphocytic leukemia","volume":"121","author":"Pettit","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/157489208784638811","article-title":"Novel purine nucleoside analogues for hematological malignancies","volume":"3","author":"Korycka","year":"2008","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.ctrv.2013.03.006_b0065","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.2174\/092986706778742918","article-title":"Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity","volume":"13","author":"Robak","year":"2006","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ctrv.2013.03.006_b0070","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.ctrv.2013.03.006_b0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1042819021000035608","article-title":"Purine nucleoside analogues in the treatment of myleoid leukemias","volume":"44","author":"Robak","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0080","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.2009.25.9630","article-title":"Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/13543784.2011.554822","article-title":"New nucleoside analogs for patients with hematological malignancies","volume":"20","author":"Robak","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2013.03.006_b0090","first-page":"3100","article-title":"Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase","volume":"62","author":"Rodriquez","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0095","first-page":"1005","article-title":"Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies","volume":"53","author":"Adkins","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2013.03.006_b0100","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1999.17.5.1574","article-title":"Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with \u201clow-grade\u201d non- Hodgkin\u2019s lymphoma and B-cell chronic lymphocytic leukemia","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0105","first-page":"1113","article-title":"Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review)","volume":"27","author":"Van den Neste","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0110","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/molecules14031183","article-title":"Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases","volume":"14","author":"Robak","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ctrv.2013.03.006_b0115","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.2174\/138161212801227005","article-title":"Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias","volume":"18","author":"Robak","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2013.03.006_b0120","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/sj.thj.6200392","article-title":"Use of fludarabine in the treatment of acute myeloid leukemia","volume":"5","author":"Jackson","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.ctrv.2013.03.006_b0125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148532","article-title":"Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia","volume":"9","author":"Estey","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428190109057986","article-title":"Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia","volume":"41","author":"Vidarsson","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hon.943","article-title":"Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloidleukaemia secondary to a previously diagnosed myelodysplastic syndrome","volume":"28","author":"Ferrara","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0140","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.leukres.2010.12.030","article-title":"Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy","volume":"35","author":"Mehta","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0145","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin \u00b1 all-trans retinoic acid \u00b1 granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0150","first-page":"1842","article-title":"FLAG (fludarabine+high-dose cytarabine+G-CSF): an effective and tolerable protocol for the treatment of \u2018poor risk\u2019 acute myeloid leukemias","volume":"8","author":"Visani","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2013.03.006_b0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1034\/j.1600-0609.2002.01651.x","article-title":"De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG)","volume":"68","author":"Ferrara","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1034\/j.1600-0609.2000.90066.x","article-title":"Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG)","volume":"64","author":"Tedeschi","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0165","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2003-07-2195","article-title":"The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients","volume":"103","author":"Ossenkoppele","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W","article-title":"Fludarabine cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia","volume":"58","author":"Montillo","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0175","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0145-2126(02)00003-6","article-title":"FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies","volume":"26","author":"de la Rubia","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002770050541","article-title":"Phase II trial or idarubicin, fludarabine, cytosine arabinoside and filigastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML","volume":"78","author":"Steinmetz","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10428190109057932","article-title":"Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia","volume":"40","author":"Russo","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.23337","article-title":"Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients","volume":"88","author":"Kim","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0195","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/08880018.2010.493578","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience","volume":"27","author":"Tavil","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0200","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ajh.21545","article-title":"Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF","volume":"84","author":"Martin","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0205","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/039463201102400316","article-title":"Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience","volume":"24","author":"Melillo","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0210","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00277-004-0927-y","article-title":"Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia","volume":"83","author":"Clavio","year":"2004","journal-title":"Ann Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2013.03.006_b0215","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/sj.thj.6200392","article-title":"Use of fludarabine in the treatment of acute myeloid leukemia","volume":"5","author":"Jackson","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.ctrv.2013.03.006_b0220","first-page":"740","article-title":"Phase I and II study of fludarabine phosphate in leukemia therapeutic efficacy with delayed central nervous system toxicity","volume":"4","author":"Warell","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0225","first-page":"5953","article-title":"Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study","volume":"46","author":"Spriggs","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0230","first-page":"1225","article-title":"Central nervous system toxicity of fludarabine phosphate","volume":"70","author":"Chun","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2013.03.006_b0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199409052690","article-title":"The expanding role of fludarabine in hematologic malignancies","volume":"14","author":"Keating","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0240","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-04-0097","article-title":"A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia","volume":"10","author":"Cooper","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.leukres.2003.08.013","article-title":"A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia","volume":"28","author":"Giles","year":"2004","journal-title":"Leuk Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2013.03.006_b0250","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1007\/s12032-010-9653-6","article-title":"FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia","volume":"28","author":"Eom","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0255","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00280-003-0671-3","article-title":"Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia","volume":"52","author":"Tsimberidou","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0260","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cncr.11239","article-title":"Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.03.006_b0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clml.2012.03.003","article-title":"Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed\/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia","volume":"12","author":"Jabbour","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2013.03.006_b0270","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/10428194.2012.713479","article-title":"Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effectivesalvage therapy option for acute myeloid leukemia at first relapse","volume":"54","author":"Fong","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/157489206775246467","article-title":"Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies","volume":"1","author":"Robak","year":"2006","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.ctrv.2013.03.006_b0280","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2013.03.006_b0285","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1200\/JCO.1991.9.3.416","article-title":"A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia","volume":"9","author":"Santana","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0290","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.1992.10.3.364","article-title":"2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia","volume":"10","author":"Santana","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0295","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1200\/JCO.2001.19.11.2804","article-title":"Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic disease","volume":"19","author":"Krance","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0300","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V84.4.1237.1237","article-title":"Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia","volume":"84","author":"Santana","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0305","first-page":"1563","article-title":"Clinical and laboratory studies of 2-chlorodeoxyadenosine+cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults","volume":"10","author":"Kornblau","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2013.03.006_b0310","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","article-title":"Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions","volume":"87","author":"Gandhi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0315","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(00)00043-6","article-title":"Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed\/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995","volume":"24","author":"Gordon","year":"2000","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002770050355","article-title":"2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia","volume":"76","author":"Van den Neste","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0325","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1182\/blood.V84.10.3429.3429","article-title":"Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeleoid leukemia","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0330","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428190009053545","article-title":"Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"39","author":"Robak","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0335","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2003.00122.x","volume":"71","author":"Wrzesie\u0144-Ku\u015b","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0340","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","article-title":"Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens","volume":"35","author":"Price","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0345","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-005-1046-0","volume":"84","author":"Wrzesie\u0144-Ku\u015b","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2009.n.058","article-title":"Cladribine in the treatment of acute myeloid leukemia: a single-institution experience","volume":"9","author":"Martin","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0360","first-page":"123a","article-title":"No additional toxicity from cladribine (CdA) as primary treatment of acute myeloid leukemia in elderly patients: results from a randomized phase II study from the Leukemia Group of Middle Sweden (LGMS)","volume":"98","author":"Juliusson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0365","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter phase III study","volume":"18","author":"Ho\u0142owiecki","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2013.03.006_b0370","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0375","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cncr.24712","article-title":"Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia","volume":"116","author":"Inaba","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.03.006_b0380","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2009.30","article-title":"Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial","volume":"23","author":"Rubnitz","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2013.03.006_b0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/ehm.09.70","article-title":"Clofarabine in leukemia","volume":"3","author":"Ghanem","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0390","article-title":"The role of clofarabine in acute myeloid leukemia","author":"Ghanem","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0395","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2174\/138955709788452586","article-title":"Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity","volume":"9","author":"Lech-Maranda","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ctrv.2013.03.006_b0400","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","article-title":"Discovery and development of clofarabine: a nucleoside analogue for treating cancer","volume":"5","author":"Bonate","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2013.03.006_b0405","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems","volume":"69","author":"King","year":"2006","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0410","first-page":"459","article-title":"Clofarabine (2-chloro-2\u2032-fluoro-2\u2032-deoxyarabinosyladenine)\u2013biochemical aspects of anticancer activity","volume":"68","author":"Majda","year":"2011","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.ctrv.2013.03.006_b0415","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0420","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","article-title":"Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers","volume":"21","author":"Kantarjian","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0425","first-page":"248a","article-title":"A Phase 2 evaluation of single agent clofarabine treatment for older patients with AML who are not considered fit forintensive chemotherapy","volume":"104","author":"Burnett","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2013.03.006_b0430","first-page":"562a","article-title":"Effectiveness of clofarabine in eldery AML patients with adverse cytogenetics unfit for intensive chemotherapy","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2013.03.006_b0435","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0440","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/10428190701545644","article-title":"Clofarabine: past present and future","volume":"48","author":"Kantarjian","year":"2007","journal-title":"Leuk lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0445","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2009.23.3130","article-title":"Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavourable prognostic factors","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0450","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","article-title":"Results of a phase 1\u20132 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias","volume":"105","author":"Faderl","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0455","first-page":"250a","article-title":"Clofarabine plus cytarabine (Ara-C) combination is active in newly diagnosed patients (PTS)\u2a7dage 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"104","author":"Faderl","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2013.03.006_b0460","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","article-title":"Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50years of age or older","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0465","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0470","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0475","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1002\/cncr.27429","article-title":"Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients","volume":"118","author":"Faderl","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.03.006_b0480","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2009.26.4242","article-title":"European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy","volume":"28","author":"Burnett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0485","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2141.2011.08831.x","article-title":"Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia","volume":"155","author":"Becker","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0490","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3109\/10428194.2011.647313","article-title":"A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia","volume":"53","author":"Foster","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0495","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.2011.08940.x","article-title":"Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)","volume":"156","author":"Amadori","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0500","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1200\/JCO.2008.18.8706","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Jeha","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0505","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3109\/10428194.2012.663915","article-title":"Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients","volume":"53","author":"Miano","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2013.03.006_b0510","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2011.34.7427","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia","volume":"20","author":"Inaba","year":"2011","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ctrv.2013.03.006_b0515","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1200\/JCO.2008.18.8706","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia","volume":"10","author":"Jeha","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0520","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0525","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.23167","article-title":"Clofarabine-based chemotherapy for relapsed\/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience","volume":"87","author":"Barba","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0530","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2010.08387.x","article-title":"Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0535","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.2009.07882.x","article-title":"Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children withrefractory\/multiple relapsed acute lymphoblastic leukaemia","volume":"147","author":"Locatelli","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0540","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0545","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/pbc.22321","article-title":"Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia","volume":"54","author":"Steinherz","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2013.03.006_b0550","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2141.2011.08752.x","article-title":"Early UK experience in the use of clofarabine in the treatment of relapsed and refractory pediatric acute lymphoblastic leukaemia","volume":"154","author":"O\u2019Connor","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0555","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/14796694.2.4.441","article-title":"Nelarabine: efficacy in the treatment of clinical malignancies","volume":"2","author":"Roecker","year":"2006","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0560","first-page":"3352","article-title":"2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0565","first-page":"3100","article-title":"Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase","volume":"62","author":"Rodriguez","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.03.006_b0570","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1358\/dot.2006.42.7.985638","article-title":"Nelarabine use in leukemias","volume":"42","author":"Kisor","year":"2006","journal-title":"Drugs Today"},{"key":"10.1016\/j.ctrv.2013.03.006_b0575","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.cco.0000245326.65152.af","article-title":"Clofarabine and nelarabine: two new purine nucleoside analogs","volume":"18","author":"Ghandi","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0580","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0585","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children andyoung adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0590","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0595","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0600","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0605","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011;118:3504\u201311.","DOI":"10.1182\/blood-2011-01-329441"},{"key":"10.1016\/j.ctrv.2013.03.006_b0610","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.clinthera.2007.09.002","article-title":"Nelarabine: a novel purine antimetabolite antineoplastic agent","volume":"29","author":"Buie","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ctrv.2013.03.006_b0615","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","article-title":"FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"13","author":"Cohen","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2013.03.006_b0620","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/fon.10.83","article-title":"Forodesine: review of preclinical and clinical data","volume":"6","author":"Al-Kali","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0625","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/138955707781662636","article-title":"Forodesine (BCX-1777, immucillin H)\u2013a new purine nucleoside analogue: mechanism of action and potential clinical application","volume":"7","author":"Korycka","year":"2007","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ctrv.2013.03.006_b0630","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm030305z","article-title":"Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase","volume":"46","author":"Evans","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2013.03.006_b0635","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/bi980658d","article-title":"One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase","volume":"37","author":"Miles","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2013.03.006_b0640","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Intern Immunopharmacol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0645","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2006-03-007468","article-title":"Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells","volume":"108","author":"Balakrishnan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0650","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0655","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood-2011-02-337840","article-title":"In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia","volume":"118","author":"Homminga","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.03.006_b0660","first-page":"259a","article-title":"Forodesine (FodosineTM), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (Phase II study)","volume":"106","author":"Furman","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2013.03.006_b0665","first-page":"427a","article-title":"Forodesine in patients with refractory\/relapsed T-ALL can induce prolonged stable remission with minimal toxicity before and after allogeneic hematopoietic stem cell transplantation","volume":"106","author":"Stelljes","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6 Suppl. 5","key":"10.1016\/j.ctrv.2013.03.006_b0670","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2007.11.005","article-title":"Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?","volume":"34","author":"Gore","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2013.03.006_b0675","first-page":"750a","article-title":"Intravenous Forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I\/II studies in patients with B-Cell acute lymphoblastic leukemia","volume":"104","author":"Furman","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2013.03.006_b0680","first-page":"533a","article-title":"Phase II study of forodesine, a PNP","volume":"108","author":"Ritchie","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T08:08:41Z","timestamp":1715155721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":136,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0305737213000698"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}